TECNOTREE
7.8.2024 11:59:35 CEST | Business Wire | Press release
Tecnotree, a global leader in digital platforms and services for AI, 5G, and cloud-native technologies, has been mentioned in three different 2024 Gartner Hype Cycle reports, recently published. Tecnotree has been cited under the categories of Hype Cycle for Enterprise Communication Services, Private Mobile Network Services, and Operations and Automation in Communications Industry, 2024. We believe that these recognitions highlight Tecnotree’s excellence in Partner Ecosystem Management Platforms for CSPs and CSP Digital Marketplaces for Tecnotree Moments Partner Ecosystem Platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807343127/en/
Tecnotree Recognized in 3 Different 2024 Gartner® Hype Cycle™ Reports, for Partner Ecosystem Management Platforms for CSPs, CSP Digital Marketplaces, and AI for CSP Customer Interactions Categories (Graphic: Business Wire)
As per Gartner, “Gartner Hype Cycles provide a graphic representation of the maturity and adoption of technologies and applications, and how they are potentially relevant to solving real business problems and exploiting new opportunities. Gartner Hype Cycle methodology gives you a view of how a technology or application will evolve over time, providing a sound source of insight to manage its deployment within the context of your specific business goals.” Digital marketplaces are an increasingly important part of the CSPs’ go-to-market strategy for digital services and small-and-midsize-business (SMB) and consumer segments. CSPs can enrich their offerings with partner solutions, drive data insights on buyer behavior, and implement automation for faster cycles and improved digital engagement. CSPs can use marketplaces to differentiate from competitors through expanding portfolio with partner offerings, ease-of-use, automation, composable bundles, verticalization and locally tailored offerings.
Tecnotree Moments powered by TM Forum certified Open APIs and Open Digital Architecture (ODA) compliant, provides superior digital experience management operations with advertising and partner led campaign management solutions for aim driven product recommendations, customer journey orchestration, partner management, content and channel personalisation, and dynamic loyalty programs. The Tecnotree Moments multi experience platform using Azure and AWS cloud infrastructure with multitenancy capabilities. The low/no code platform provides intelligence enabled customer experience, based on AI & ML and automation utilizing cloud technologies.
Tecnotree Moments, marketplace accelerates time to market, extends outreach to target segments, expands partner ecosystems, and speeds up the sales cycle. For CSPs, marketplaces target increased self-service and digital engagement, revenue growth, tailored solutions that can be composed based on the needs of each buyer, and actionable data insights on purchase behavior that can inform product developers and enrich the support of ecosystem partners.
Padma Ravichander, CEO, Tecnotree Corporation said, “We are thrilled to be acknowledged in three of the Gartner Hype Cycles. We believe that this recognition underscores our forward-looking vision unwavering commitment to delivering unparalleled value by redefining digital experiences and enhancing revenue monetization capabilities for our customers. Leveraging AI, 5G, and cloud-native technologies, we drive innovation that empowers CSPs with personalized, highly secure solutions. Our inclusion in these reports validates our dedication to pushing the boundaries and continuously expanding our use of AI applications to improve productivity, efficiency, and customer experience.”
Gartner, Hype Cycle for Customer Experience and Monetization in the Communications Industry, 2024, By Susan Welsh de Grimaldo, Pulkit Pandey, 25 July 2024.
Gartner, Hype Cycle for Enterprise Communication Services, 2024, By Khurram Shahzad, 16 July 2024.
Gartner, Hype Cycle for Operations and Automation in the Communications Industry, 2024, By Mounish Rai, Amresh Nandan, 23 July 2024.
Gartner Research Methodologies, Gartner Hype Cycle, August 5, 2024, https://www.gartner.com/en/research/methodologies/gartner-hype-cycle
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree leads the way on the TM Forum Open API Conformance with 59 certified Open APIs including 9 real-world open APIs, a testament to the company's commitment to excellence, and continuously striving to deliver differentiated experiences and services to both CSPs and DSPs. Our agile and open-source digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807343127/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
